EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

KTE-X19 autologous anti-CD19 CAR T-cell therapy in patients with R/R B-ALL: Long-term phase I ZUMA-4 results

Despite the availability of novel therapies, clinical outcomes remain poor in the 10‒20% of...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

The UKALL-HeH model could potentially redefine low-risk high hyperdiploidy in pediatric acute lymphoblastic leukemia

Approximately 30% of pediatric patients with acute lymphoblastic leukemia (ALL)...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

When is it safe to schedule an allo-HSCT after COVID-19 infection?

During the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

How are transplant options evolving for patients with ALL?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Aaron Logan, UCSF, San Francisco, US. We asked,...

Does current reporting on CAR T-cell therapy in clinical trials overestimate efficacy? Why the distinction between ITT and mITT populations is important

Anti-CD19 chimeric antigen receptor (CAR)...

Phase I ZUMA-4 trial: Long-term follow-up of brexu-cel in pediatric/adolescent R/R B-ALL

During the EHA2021 Virtual Congress, the ALL Hub spoke with André Baruchel, Hôpital Robert-Debré, Paris, FR,...

KTE-X19 autologous anti-CD19 CAR T-cell therapy in patients with R/R B-ALL: Long-term phase I ZUMA-4 results

Despite the availability of novel therapies, clinical outcomes remain poor in the 10‒20% of...